193 related articles for article (PubMed ID: 32975478)
1. The requirement for cyclin E in c-Myc overexpressing breast cancers.
Zhou Y; Geng Y; Zhang Y; Zhou Y; Chu C; Sharma S; Fassl A; Butter D; Sicinski P
Cell Cycle; 2020 Oct; 19(20):2589-2599. PubMed ID: 32975478
[TBL] [Abstract][Full Text] [Related]
2. Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.
Caldon CE; Sergio CM; Schütte J; Boersma MN; Sutherland RL; Carroll JS; Musgrove EA
Mol Cell Biol; 2009 Sep; 29(17):4623-39. PubMed ID: 19564413
[TBL] [Abstract][Full Text] [Related]
3. Kinase-independent function of E-type cyclins in liver cancer.
Geng Y; Michowski W; Chick JM; Wang YE; Jecrois ME; Sweeney KE; Liu L; Han RC; Ke N; Zagozdzon A; Sicinska E; Bronson RT; Gygi SP; Sicinski P
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):1015-1020. PubMed ID: 29339491
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclins E1 and E2 during mouse development and in neoplasia.
Geng Y; Yu Q; Whoriskey W; Dick F; Tsai KY; Ford HL; Biswas DK; Pardee AB; Amati B; Jacks T; Richardson A; Dyson N; Sicinski P
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13138-43. PubMed ID: 11687642
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
6. Proteomic Landscape of Tissue-Specific Cyclin E Functions in Vivo.
Odajima J; Saini S; Jung P; Ndassa-Colday Y; Ficaro S; Geng Y; Marco E; Michowski W; Wang YE; DeCaprio JA; Litovchick L; Marto J; Sicinski P
PLoS Genet; 2016 Nov; 12(11):e1006429. PubMed ID: 27828963
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
[TBL] [Abstract][Full Text] [Related]
8. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA
Mol Cancer Ther; 2012 Jul; 11(7):1488-99. PubMed ID: 22564725
[TBL] [Abstract][Full Text] [Related]
9. Loss of cyclin E requirement in cell growth of an oral squamous cell carcinoma cell line implies deregulation of its downstream pathway.
Yamada S; Sumrejkanchanakij P; Amagasa T; Ikeda MA
Int J Cancer; 2004 Aug; 111(1):17-22. PubMed ID: 15185338
[TBL] [Abstract][Full Text] [Related]
10. Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.
Caldon CE; Sergio CM; Burgess A; Deans AJ; Sutherland RL; Musgrove EA
Cell Cycle; 2013 Feb; 12(4):606-17. PubMed ID: 23324395
[TBL] [Abstract][Full Text] [Related]
11. Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women.
Khan F; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
Ann Diagn Pathol; 2018 Jun; 34():170-174. PubMed ID: 29715580
[TBL] [Abstract][Full Text] [Related]
12. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis.
Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB
Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672
[TBL] [Abstract][Full Text] [Related]
14. Cyclin A but not cyclin D1 is essential for c-myc-modulated cell-cycle progression.
Qi Y; Tu Y; Yang D; Chen Q; Xiao J; Chen Y; Fu J; Xiao X; Zhou Z
J Cell Physiol; 2007 Jan; 210(1):63-71. PubMed ID: 17013808
[TBL] [Abstract][Full Text] [Related]
15. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
Prall OW; Rogan EM; Musgrove EA; Watts CK; Sutherland RL
Mol Cell Biol; 1998 Aug; 18(8):4499-508. PubMed ID: 9671459
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.
Agarwal R; Gonzalez-Angulo AM; Myhre S; Carey M; Lee JS; Overgaard J; Alsner J; Stemke-Hale K; Lluch A; Neve RM; Kuo WL; Sorlie T; Sahin A; Valero V; Keyomarsi K; Gray JW; Borresen-Dale AL; Mills GB; Hennessy BT
Clin Cancer Res; 2009 Jun; 15(11):3654-62. PubMed ID: 19470724
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cyclin E1 expression in human pluripotent stem cells and derived neural progeny.
Rodríguez Varela MS; Mucci S; Videla Richardson GA; Morris Hanon O; Furmento VA; Miriuka SG; Sevlever GE; Scassa ME; Romorini L
Cell Cycle; 2018; 17(14):1721-1744. PubMed ID: 29995582
[TBL] [Abstract][Full Text] [Related]
18. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity.
Berns K; Hijmans EM; Bernards R
Oncogene; 1997 Sep; 15(11):1347-56. PubMed ID: 9315103
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.
Sonntag R; Giebeler N; Nevzorova YA; Bangen JM; Fahrenkamp D; Lambertz D; Haas U; Hu W; Gassler N; Cubero FJ; Müller-Newen G; Abdallah AT; Weiskirchen R; Ticconi F; Costa IG; Barbacid M; Trautwein C; Liedtke C
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):9282-9287. PubMed ID: 30150405
[TBL] [Abstract][Full Text] [Related]
20. β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
Xu J; Chen Y; Huo D; Khramtsov A; Khramtsova G; Zhang C; Goss KH; Olopade OI
Mol Carcinog; 2016 May; 55(5):431-9. PubMed ID: 25663530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
